RPG Life Sciences surges after getting EUGMP certification for formulation facility at Ankleshwar

Image
Capital Market
Last Updated : Apr 06 2016 | 11:13 AM IST

RPG Life Sciences jumped 8.44% to Rs 253.20 at 10:41 IST on BSE after the company received GMP Certificate for its formulation manufacturing facility in Ankleshwar, Gujarat.

The announcement was made after market hours yesterday, 5 April 2016.

Meanwhile, the S&P BSE Sensex was up 19.35 points, or 0.08%, to 24,902.94

On BSE, so far 54,000 shares were traded in the counter as against an average daily volume of 17,320 shares in the past one quarter. The stock hit a high of Rs 259.90 and a low of Rs 246.60 so far during the day. The stock had hit a record high of Rs 360.60 on 3 December 2015. The stock had hit a 52-week low of Rs 130.50 on 24 April 2015. The stock had underperformed the market over the past one month till 5 April 2016, falling 2.18% compared with Sensex's 0.96% rise. The scrip had also underperformed the market in past one quarter, sliding 28.68% as against Sensex's 2.72% fall.

The small-cap company has an equity capital of Rs 13.23 crore. Face value per share is Rs 8.

RPG Life Sciences said that the company has received good manufacturing practice (GMP) certificate from Bavarian Authority, a competent authority in Germany, as per EUGMP standards for its formulation manufacturing facility at GIDC Industrial Estate, Ankleshwar, Gujarat. Bavarian Authority conducted audit of the manufacturing facility in early March 2016, RPG Life Sciences said. CT Renganathan, Managing Director, RPG Life Sciences said that the certification will help in boosting sales by expanding the company's geographical presence in the European markets.

RPG Life Sciences' net profit jumped 84.6% to Rs 4.67 crore on 24.8% rise in total income to Rs 73.21 crore in Q3 December 2015 over Q3 December 2014.

RPG Life Sciences is an integrated pharmaceutical company operating in the domestic and international markets in the Branded Formulations, Global Generics, Synthetic and Fermentation APIs space. The company is a research-based pharmaceutical company producing a wide range of medicines.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 06 2016 | 10:52 AM IST

Next Story